PIN1 and familial pancreatic carcinoma: Thus, our study might expand the clinical implication of the pharmacological inhibition of PIN1 by ATRA in the treatment of cancers with wild-type VHL. Although our study is mainly focused in TNBC, further investigation need warranted especially in pancreatic cancer and other lethal cancers with worse prognosis and no targeted therapies.